| 词条 | Urelumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 470620242 | type = mab | image = | alt = | mab_type = mab | source = u | target = CD137 | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 934823-49-1 | ATC_prefix = none | ATC_suffix = | PubChem = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | KEGG = D09984 | C=6502 | H=9972 | N=1712 | O=2030 | S=44 | molecular_weight = 145.8 kg/mol | synonyms = BMS-663513 }}Urelumab (BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors.[1] Urelumab targets the extracellular domain of CD137.[2] It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.[3] The first phase I trial began in 2006 and final results were published in 2015.[4] Current clinical trials combine urelumab with chemotherapy (NCT00351325), chemoradiation (NCT00461110), ipilimumab (NCT00803374), rituximab (NCT01775631, NCT02420938), cetuximab (NCT02110082), and elotuzumab (NCT02252263), nivolumab (NCT02253992) for metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma. A biomarker study using CyTOF is also underway.[5] References1. ^{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/urelumab.pdf}} {{Monoclonals for immune system}}{{Cytokine receptor modulators}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^http://web.stanford.edu/~sdutt/PDF/2015_SD_yonezawa.pdf 3. ^{{cite web|title= Urelumab|publisher=National Cancer Institute|url=http://www.cancer.gov/drugdictionary?cdrid=489120}} 4. ^https://clinicaltrials.gov/ct2/show/NCT00309023?term=NCT00309023&rank=1 5. ^http://web.stanford.edu/~sdutt/PDF/2015_SD_yonezawa.pdf 3 : Bristol-Myers Squibb|Monoclonal antibodies|Experimental cancer drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。